This study will be conducted to evaluate the efficacy and safety of YOLT-203 in children and adults with Primary Hyperoxaluria Type 1. After the initial rando…

Primary Hyperoxaluria Type 1PH1

~Estimated

~$10 – $8,750

YolTech Therapeutics Co., LtdNCT07587021

Phase 2

A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis

The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.

Primary Hyperoxaluria Type 1End Stage Renal Disease

~Estimated

~$10 – $8,750

Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyNCT04580420

Phase 1

A Phase 1/2 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ABO-101 in Participants With Primary Hyperoxaluria Type 1 (PH1)

The goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperox…

Primary Hyperoxaluria Type 1 (PH1)

~Estimated

~$10 – $8,750

Arbor BiotechnologiesNCT06839235